Clarivate’s ‘drugs to watch’ list signals high prices to come
11-02-2020
Antitrust regulators to increase scrutiny of biosimilar deals
04-02-2020
Jarretera / Shutterstock.com
US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
FDA, FTC, US Food and Drug Administration, Stephen Han, Federal Trade Commission, Joe Simons, biologics, biosimilars, antitrust
